dipyridamole has been researched along with HIV Coinfection in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1." | 9.34 | A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. ( Abebe, KZ; Borowski, L; Comer, D; Cyktor, J; Gillespie, DG; Jackson, EK; Klamar-Blain, C; Macatangay, BJC; Mellors, JW; Riddler, SA; Rinaldo, CR, 2020) |
| " We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1." | 5.34 | A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. ( Abebe, KZ; Borowski, L; Comer, D; Cyktor, J; Gillespie, DG; Jackson, EK; Klamar-Blain, C; Macatangay, BJC; Mellors, JW; Riddler, SA; Rinaldo, CR, 2020) |
| "Dipyridamole (DP) is a widely used coronary vasodilator and antithrombotic drug." | 2.38 | [A new drug in a new role: dipyridamole in the treatment of HIV-1 infections?]. ( Szebeni, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mallarino-Haeger, C | 1 |
| Abebe, KZ | 2 |
| Jackson, EK | 2 |
| Zyhowski, A | 1 |
| Klamar-Blain, C | 2 |
| Cyktor, JC | 1 |
| Comer, D | 2 |
| Brand, RM | 1 |
| Gillespie, DG | 2 |
| Holleran, K | 1 |
| Mellors, JW | 2 |
| McGowan, I | 1 |
| Riddler, SA | 2 |
| Macatangay, BJC | 2 |
| Utay, NS | 1 |
| Overton, ET | 1 |
| Cyktor, J | 1 |
| Borowski, L | 1 |
| Rinaldo, CR | 1 |
| Szebeni, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection[NCT04410328] | Phase 3 | 99 participants (Actual) | Interventional | 2020-10-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dipyridamole and HIV Coinfection
| Article | Year |
|---|---|
[A new drug in a new role: dipyridamole in the treatment of HIV-1 infections?].
Topics: Acquired Immunodeficiency Syndrome; Dipyridamole; Drug Therapy, Combination; HIV Infections; HIV-1; | 1991 |
2 trials available for dipyridamole and HIV Coinfection
| Article | Year |
|---|---|
Brief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy.
Topics: Adenosine; Anti-HIV Agents; Biopsy; CD8-Positive T-Lymphocytes; Cross-Over Studies; Dipyridamole; Fe | 2020 |
A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.
Topics: Adolescent; Adult; Biomarkers; Chronic Disease; Dipyridamole; Double-Blind Method; HIV Infections; H | 2020 |
1 other study available for dipyridamole and HIV Coinfection
| Article | Year |
|---|---|
Immune Activation and Inflammation in People With Human Immunodeficiency Virus: Challenging Targets.
Topics: Animals; Dipyridamole; HIV; HIV Infections; Humans; Inflammation; Simian Acquired Immunodeficiency S | 2020 |